Nabuton
Generic Name
Nabumetone
Manufacturer
Beximco Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| nabuton 500 mg tablet | ৳ 15.00 | ৳ 150.00 |
Description
Overview of the medicine
Nabuton 500 mg Tablet contains Nabumetone, a non-steroidal anti-inflammatory drug (NSAID). It is used for the symptomatic treatment of osteoarthritis and rheumatoid arthritis, helping to reduce pain, inflammation, and stiffness. Nabumetone is a prodrug that gets converted into its active metabolite in the body.
Uses & Indications
Dosage
Adults
Typically 500 mg to 1000 mg once daily, or 500 mg twice daily. Doses up to 1500-2000 mg daily may be given for severe cases, usually as 1000 mg once daily or 500 mg twice daily.
Elderly
Generally, no special dosage adjustment is required, but caution is advised in elderly patients due to increased risk of side effects, especially gastrointestinal. Lower doses may be considered.
Renal_impairment
Use with caution in patients with mild to moderate renal impairment. For severe renal impairment (CrCl <30 mL/min), not recommended or significantly reduced doses with close monitoring.
How to Take
Take orally, preferably with food or after a meal, to minimize gastrointestinal upset. Swallow the tablet whole with a glass of water; do not crush, chew, or break it.
Mechanism of Action
Nabumetone is a prodrug that is converted to its active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA). 6-MNA inhibits cyclooxygenase (COX-1 and COX-2) enzymes, primarily COX-2, which are responsible for the synthesis of prostaglandins. By reducing prostaglandin production, it decreases inflammation, pain, and fever.
Pharmacokinetics
Onset
Analgesic effects may be noted within a few hours, but full anti-inflammatory effects for chronic conditions like arthritis may take 1-2 weeks.
Excretion
Approximately 80% of the dose is excreted in the urine, primarily as conjugated metabolites of 6-MNA, with a smaller portion (about 10%) excreted in feces.
Half life
The half-life of the active metabolite (6-MNA) is approximately 22-24 hours, allowing for once-daily dosing.
Absorption
Nabumetone is well absorbed from the gastrointestinal tract. It is a prodrug that undergoes hepatic metabolism to its active metabolite, 6-MNA. Peak plasma concentrations of 6-MNA are reached in approximately 3-6 hours after oral administration. Food can enhance its absorption.
Metabolism
Nabumetone is rapidly and extensively metabolized in the liver to its active metabolite, 6-MNA, through oxidative O-demethylation.
Side Effects
Contraindications
- •Known hypersensitivity to Nabumetone or other NSAIDs
- •History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
- •Active gastrointestinal bleeding or peptic ulcer disease
- •Severe renal or hepatic impairment
- •Last trimester of pregnancy
- •Peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery
Drug Interactions
Lithium
May increase plasma lithium levels, leading to toxicity.
Methotrexate
May increase methotrexate plasma levels, potentially leading to toxicity.
Cyclosporine, Tacrolimus
Increased risk of nephrotoxicity.
Diuretics (e.g., Furosemide)
Reduced diuretic and antihypertensive effects.
Anticoagulants (e.g., Warfarin)
Increased risk of bleeding due to potentiation of anticoagulant effect.
ACE Inhibitors & Angiotensin Receptor Blockers (ARBs)
Reduced antihypertensive effect and increased risk of renal impairment, especially in elderly or dehydrated patients.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose may include lethargy, drowsiness, nausea, vomiting, epigastric pain, and gastrointestinal bleeding. Rarely, hypertension, acute renal failure, respiratory depression, and coma may occur. Management is primarily supportive and symptomatic. Gastric decontamination (e.g., activated charcoal) may be considered if ingestion is recent. Monitor renal function and electrolyte levels.
Pregnancy & Lactation
Pregnancy Category C (first two trimesters), D (third trimester). Avoid in the third trimester of pregnancy due to potential for premature closure of the fetal ductus arteriosus and potential inhibition of uterine contractions. Use with caution during lactation; small amounts may pass into breast milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24 to 36 months from the date of manufacture.
Availability
Pharmacies, hospitals
Approval Status
Approved
Patent Status
Generic available
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
